Funding Opportunity RFA-HG-19-002 from the NIH Guide for Grants and Contracts. The National Human Genome Research Institute (NHGRI) seeks applications for the production of High Quality Human Reference Genomes (HQRG) as a component of the NHGRI Human Genome Reference Program (HGRP). One aim of the HGRP is to develop a genome reference that is representative of human population genetic diversity. To help achieve this goal, this HQRG initiative is expected to establish metrics for high quality-genome assemblies; collaborate with other HGRC awardees on sample selection and prioritization; produce on the order of 350 haplotype-resolved human genomes, using diverse samples consented for full data release; and provide capacity to help resolve error reports received by the HGRC. This and related FOA's will replace and update NHGRI's current contributions to the Genome Reference Consortium https://www.ncbi.nlm.nih.gov/.
Funding Opportunity RFA-HG-19-004 from the NIH Guide for Grants and Contracts. The National Human Genome Research Institute (NHGRI) seeks applications for a Human Genome Reference Center (HGRC). The HGRC will be the central group within a multi-component Human Genome Reference Program (HGRP) that will maintain and update the human genome reference and provide it to the scientific community. This group will also work with other HGRP members and the larger scientific community to prioritize sample choice and develop quality standards for new high-quality genome assemblies to add to the human genome reference; support state-of-the-art representations of alternate haplotypes (including representations developed by other program components); identify and respond to diverse community needs (e.g. clinical and basic) for use of the human genome reference; liaise or coordinate with other (international) resources that represent human genomic sequence and variation and/or that provide reference resources for human and other organisms. This and related FOA's will replace and update NHGRI's current contributions to the Genome Reference Consortium https://www.ncbi.nlm.nih.gov/grc
Funding Opportunity RFA-HG-19-003 from the NIH Guide for Grants and Contracts. The National Human Genome Research Institute (NHGRI) seeks to support research and development for a next-generation genome reference representation. This pangenome resource will be able to capture all human genome variation and support scalable analysis in a software framework that will set a robust foundation for open science. Projects will develop improved representations for computing on the information contained within the increasing numbers of diverse genome assemblies that will make up the human reference sequence going forwards. While the high-level concept of the pangenome as a graph is well-established, further research and development is needed to refine and implement a practical representation and implementation to enable active use of population-scale variation. Software is needed that can demonstrate efficiency, scalability, computational speed, ease of use, and the ability to foster adoption of the reference and analysis tool development for a wide range of purposes. The FOA will fund multiple projects that will together help set benchmarks and standards in this domain. A primary requirement is to adhere to a high level of open science including open-source tools, standards, specifications, and robust software engineering to enable this core resource to be widely integrated in the larger community and support outside contributions. Robust design is also expected to provide a foundation for independent efforts that may have enhanced privacy and security requirements.
Funding Opportunity RFA-DK-18-028 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to seek applications for the Developmental Centers for Interdisciplinary Research in Benign Urology Program (P20). Among the goals of this Program is to further advance research in benign genitourinary diseases and disorders by building research teams and facilitating resources generation and sharing. The research teams should be composed of individuals with complementary expertise who propose to either develop innovative resources (Resource Development Projects) or a new research project (Scientific Research Projects) that utilize integrative approaches to address questions relevant to benign genitourinary diseases or disorders. While NIH defined clinical trials are not allowed, studies involving human subjects or tissues are encouraged. Resources developed by the Resource Development Projects will be shared upon validation while resources developed within the Scientific Research Projects will be shared at the end or termination of the award, as appropriate and consistent with the program goal of further advancing research. Each Developmental Center is centered on a single Project and must contain an Administrative Core and an Educational Enrichment Program. As part of the efforts of the Division of Kidney, Urologic and Hematologic Diseases (DKUH) to expand and enhance benign urology research, the Developmental Centers Program will work in partnership with the George M. O'Brien Urology Cooperative Research Centers Program (U54) and the Multidisciplinary K12 Urologic Research (KURe and UroEpi) Career Development Programs.
Funding Opportunity PAR-19-176 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) supports exploratory research projects aimed at developing cryogenic or other long-term preservation and revival approaches for Drosophila or zebrafish genetic stocks, which are essential laboratory animal models for biomedical research. The proposed project should address critical knowledge and technology gaps and describe approaches towards the development of reliable, easy-to-use and cost effective cryogenic or other long-term preservation and revival methods for wild-type and mutant strains of Drosophila or zebrafish.
Funding Opportunity PAR-19-177 from the NIH Guide for Grants and Contracts. The High-End Instrumentation (HEI) Grant Program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of expensive, specialized, commercially available instruments or integrated systems. The minimum award is $600,001. The maximum award is $2,000,000. Types of instruments supported include, but are not limited to: X-ray diffraction systems, nuclear magnetic resonance (NMR) and mass spectrometers, DNA and protein sequencers, biosensors, electron and confocal microscopes, cell-sorters, and biomedical imagers.
Funding Opportunity RFA-NS-19-027 from the NIH Guide for Grants and Contracts. This FOA invites applications that propose to develop, characterize and validate innovative human cellular model systems that recapitulate phenotypic, mechanistic and neuropathological hallmarks of Alzheimers Disease-Related Dementias (ADRDs). Model systems will be expected to capture the complex, multi-faceted proteinopathies and/or vascular pathology observed in ADRDs, with multiple cell types represented in each model. Years 3-5 will focus on the extensive characterization and perturbation of the cellular model systems. The overall goal of this FOA is to establish next generation human cellular model systems for ADRDs to serve as tools to interrogate molecular disease mechanisms and identify potential therapeutic targets.
Funding Opportunity RFA-FD-19-002 from the NIH Guide for Grants and Contracts. Cardiovascular toxicity is a leading cause of drug attrition in drug development. Proarrhythmia, QT prolongation and Torsade de Point (TdP) contribute the most to this attrition and these outcomes drive the efforts spent to eliminate them from the drug discovery pipeline. Currently, these endpoints are evaluated through in vivo preclinical studies followed by a thorough-QT (TQT) study in the clinical phase. T FDA seeks new assays to replace non-clinical cardiotoxicity assessments. Specific interest is in assays based on human cells or materials, collectively covering the spectrum of cardiotoxic drug effects.
Funding Opportunity PAR-19-173 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages state-of-the-art, systematic research approaches to elucidate the role of immune system plasticity in health and in the pathogenesis of dental, oral, and craniofacial (DOC) diseases. This FOA solicits applications that will seek to determine mechanisms underlying the ability or inability of the immune system to dynamically maintain its functional role against internal and external perturbations. The expectation is that new knowledge derived from this research will facilitate development of novel, personalized immunomodulatory-based therapies that shift the balance between degenerative and regenerative processes toward regeneration disease management in a patient-specific manner across the lifespan.
Funding Opportunity PAR-19-172 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages state-of-the-art, systematic research approaches to elucidate the role of immune system plasticity in health and in the pathogenesis of dental, oral, and craniofacial (DOC) diseases. This FOA solicits applications that will seek to determine mechanisms underlying the ability or inability of the immune system to dynamically maintain its functional role against internal and external perturbations. The expectation is that new knowledge derived from this research will facilitate development of novel, personalized immunomodulatory-based therapies that shift the balance between degenerative and regenerative processes toward regeneration disease management in a patient-specific manner across the lifespan.
Funding Opportunity PA-19-174 from the NIH Guide for Grants and Contracts. This administrative supplement funding opportunity announcement is part of the Beau Biden Cancer MoonshotSM Initiative to accelerate cancer research and was developed in response to a recommendation from the Blue Ribbon Panel of experts charged with advising the National Cancer Advisory Board on the exceptional scientific opportunities that could be accelerated through this initiative. As part of the Cancer Moonshot initiative, the National Cancer Institute (NCI) created the Patient-Derived Xenograft (PDX) Development and Trial Centers Research Network (PDXNet), a collaborative network of centers of excellence focused on using patient-derived xenografts and other patient-derived models to accelerate the development of NCI investigational new drug (IND) agents (i.e., those that the NCI is developing in collaboration with pharmaceutical partners) in NCI-sponsored early phase clinical trials. This FOA supports supplemental funds to current NCI-funded research projects for new interdisciplinary collaborations between non-PDXNet investigators and PDXNet investigators to perform research within the scientific scope(s) of the parent grant and/or cooperative agreement award(s) that will lead to improved pre-clinical evaluations of novel therapeutic concepts using the large-scale PDX model collections of PDXNet, and that could ultimately be tested in NCI-sponsored clinical trials.
Funding Opportunity RFA-MH-20-202 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) invites applications to advance understanding of the role of exposure to violence on engagement and retention in HIV care, HIV medication adherence, and viral suppression, and to develop and test novel interventions to improve HIV outcomes for individuals who have experienced violence.
Funding Opportunity RFA-MH-20-201 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement invites applications to advance understanding of the role of exposure to violence on engagement and retention in HIV care, HIV medication adherence, and viral suppression, and to develop and test novel interventions to improve HIV outcomes for individuals who have experienced violence.
Funding Opportunity RFA-MH-20-200 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) invites applications to advance understanding of the role of exposure to violence on engagement and retention in HIV care, HIV medication adherence, and viral suppression, and to develop and test novel interventions to improve HIV outcomes for individuals who have experienced violence.
Funding Opportunity RFA-DK-18-025 from the NIH Guide for Grants and Contracts. This FOA will support the conduct of advanced clinical trials designed to test the outpatient clinical safety and efficacy of artificial pancreas (AP) device systems in type 1 diabetes with the objective of improving glycemic control, reducing acute complications and improving quality of life. These trials should generate data able to satisfy safety and efficacy requirements by regulatory agencies regarding the clinical testing of AP device systems.
Funding Opportunity RFA-DK-18-026 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for a Data Coordinating Center (DCC) that will support the Advanced Clinical Trials to test Artificial Pancreas device systems. The applicant must have experience serving as the DCCfor studies on complex, clinical conditions including the testing of closed loop platforms for diabetes control.?The DCC will provide overall project coordination, administration, quality control, data management, and biostatistical support.
Funding Opportunity RFA-DK-18-024 from the NIH Guide for Grants and Contracts. The purpose of the KUH/NIDDK Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) is to recruit exceptional graduate students who are recognized by their institutions for their high potential and to incentivize them to pursue a Kidney, Urologic or Hematologic (K, U, or H) postdoctoral position that ultimately positions them to become independent K, U, or H researchers. This two-phase award will facilitate completion of the doctoral dissertation and stablize the transition of highly talented Ph.D candidates from a variety of fields, including, but not limited to, engineering, statistics, data science, imaging, biochemistry and genetics into strong postdoctoral appointments that are focused on K, U or H research. It is anticipated that successful completion of this phased award will make the individual highly competitive for a subsequent NIDDK award (e.g., K99/R00, R01). Opportunities for career development activities relevant to their long-term career goals of becoming independent researchers will be provided. Graduate students who are already involved in K, U, or H research are encouraged to apply for the NIDDK F31 (PA-18-671). This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor
